Variables | Crude model | Model 1 | Model 2 | |||
---|---|---|---|---|---|---|
OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
Age ≥ 65 years | 0.83 (0.30–2.28) | 0.720 | – | – | – | – |
Male sex | 2.75 (0.93–8.10) | 0.067 | – | – | 2.29 (0.74–7.12) | 0.153 |
BMI > 22.4 (median value on study population) | 0.73 (0.26–2.06) | 0.559 | 0.58 (0.20–1.67) | 0.310 | – | – |
Bortezomib-containing therapy | 3.10 (0.86–11.10) | 0.083 | 3.11 (0.86–11.30) | 0.084 | 3.40 (0.91–12.70) | 0.069 |
Route for bortezomib administration (Intravenously) | 1.82 (0.38–8.64) | 0.451 | 1.92 (0.39–9.37) | 0.422 | – | – |
ISS stage III | 2.69 (0.98–7.38) | 0.055 | 2.48 (0.88–6.94) | 0.085 | 1.67 (0.50–5.59) | 0.409 |
β2 microglobulin > ULN | 0.79 (0.09–6.76) | 0.831 | 0.60 (0.06–5.75) | 0.661 | – | – |
Serum albumin > ULN | 1.57 (0.42–5.90) | 0.501 | 1.32 (0.33–5.33) | 0.698 | – | – |
Lactic dehydrogenase level > ULN | 0.93 (0.29–2.99) | 0.902 | 0.91 (0.28–2.96) | 0.877 | – | – |
Pretreatment SCr level > ULN | 3.32 (1.14–9.09) | 0.027 | 3.20 (1.12–9.19) | 0.030 | 2.09 (0.61–7.16) | 0.241 |
Pretreatment serum uric acid level > ULN | 2.56 (0.92–7.14) | 0.072 | 2.11 (0.73–6.08) | 0.166 | 1.71 (0.56–5.20) | 0.344 |
Serum calcium > ULN (presence of hypercalcemia) | 1.47 (0.31–6.99) | 0.631 | 1.19 (0.24–5.81) | 0.833 | – | – |
Plasma cells in bone marrow (%) | 1.00 (0.97–1.03) | 0.956 | 1.00 (0.97–1.03) | 0.990 | – | – |
Presence of plasma cell in peripheral blood | 0.99 (0.21–4.59) | 0.985 | 0.94 (0.20–1.45) | 0.936 | – | – |
Serum free light chain ratio > 1000 | 1.14 (0.14–9.51) | 0.901 | 0.96 (0.11–8.40) | 0.969 | – | – |
Hydration a | 1.23 (0.46–3.32) | 0.684 | 1.20 (0.42–3.45) | 0.729 | – | – |
Urine alkalization | 1.14 (0.31–4.28) | 0.843 | 1.07 (0.28–4.16) | 0.919 | – | – |